Table 3.

Adjusted RRs and 95% CIs of incident subtype hematopoietic cancers according to aspartame intake levels derived from aspartame-containing beverages, the NIH-AARP Diet and Health Study, 1995-2000 (n = 473,984)

Aspartame intake (mg/d)Lymphoid malignancies*,
Non–lymphoid leukemia*,
Hodgkin lymphoma
Multiple myeloma
Non–Hodgkin lymphoma
Case, N = 279
RR (95% CI)
Case, N = 57RR (95% CI)Case, N = 273RR (95% CI)Overall
Small lymphocytic lymphoma and chronic lymphocytic leukemia
Immunoblastic lymphoma and lymphoblastic lymphoma/leukemia
Case, N = 1,279RR (95% CI)Case, N = 241RR (95% CI)Case, N = 45RR (95% CI)
None291.00 (—)1271.00 (—)5921.00 (—)1091.00 (—)231.00 (—)1211.00 (—)
>0, <100280.77 (0.44-1.32)570.85 (0.62-1.17)3000.93 (0.81-1.07)601.03 (0.75-1.41)220.77 (0.42-1.42)620.93 (0.68-1.27)
≥100, <200481.39 (0.99-1.96)1771.01 (0.85-1.19)361.16 (0.79-1.71)471.31 (0.93-1.85)
≥200, <400201.13 (0.70-1.83)920.98 (0.78-1.22)361.02 (0.69-1.52)201.05 (0.65-1.70)
≥400, <600211.03 (0.64-1.66)731.06 (0.82-1.35)291.25 (0.82-1.91)
≥600450.95 (0.70-1.29)
P for trend0.340.400.910.840.400.19
  • NOTE: Cox proportional hazards regression model adjusted for age at entry (continuous), sex, and ethnicity (non–Hispanic White, non–Hispanic Black, others), BMI (weight in kilograms / height in meters squared; four categories of ≥18.5 and <25, ≥25 and <30, ≥30 and <35, and ≥35), and history of diabetes.

  • * The aspartame-cancer associations are presented separately for lymphoid malignancies and non–lymphoid leukemias, then main lymphoid malignancies of Hodgkin lymphoma, multiple myeloma, and non-Hodgkin lymphoma. In addition, two subgroups within non-Hodgkin's lymphoma are presented: (a) small lymphocytic lymphoma and chronic lymphocytic leukemia and (b) immunoblastic lymphoma and lymphoblastic lymphoma/leukemia.

  • Due to small numbers, higher aspartame categories were collapsed for subtype cancers other than non-Hodgkin lymphoma.